CXCL12 and acute myeloid leukemia: While, toxic manifestations had significantly higher incidence in CXCR4 positive cases (p 0.019) compared to CXCR negative and also with combined CXCR4positive – SDF-1 (AA/AG) genotype AML patients (p 0.023) versus CXCR4negative, or CXCR4positive with SDF-1 (GG) genotype AML patients.